Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX · Real-Time Price · USD
4.310
+0.060 (1.41%)
At close: Dec 5, 2025, 4:00 PM EST
4.280
-0.030 (-0.70%)
After-hours: Dec 5, 2025, 7:47 PM EST
Company Description
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.
The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025.
Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
Turn Therapeutics Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Bradley Burnam |
Contact Details
Address: 250 N Westlake Blvd Westlake Village, California 91362 United States | |
| Phone | 818 546 4011 |
| Website | turntherapeutics.com |
Stock Details
| Ticker Symbol | TTRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002023016 |
| CUSIP Number | 90021W105 |
| ISIN Number | US90021W1053 |
| Employer ID | 32-0456090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bradley E. Burnam | Founder, Chief Executive Officer and Director |
| Dr. Neilesh Shailesh Ghodadra M.D. | Chief Medical Officer and Director |
| Zuraiz Chaudhary | Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer |
| Mohammed Zubair | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 17, 2025 | 424B3 | Prospectus |
| Nov 17, 2025 | 424B3 | Prospectus |
| Nov 13, 2025 | 10-Q | Quarterly Report |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 4, 2025 | 8-K | Current Report |
| Oct 30, 2025 | 8-K | Current Report |
| Oct 29, 2025 | 424B5 | Filing |
| Oct 28, 2025 | 8-K | Current Report |
| Oct 22, 2025 | 8-K | Current Report |